Related Experiment Videos
[Serum ferritin and beta-2-microglobulin in multiple myeloma]
Acta Medica Austriaca
|January 1, 1982
Summary
Serum ferritin (SF) and beta 2-microglobulin (beta 2M) are significantly elevated in multiple myeloma patients. These biomarkers may aid in monitoring disease progression, especially when standard paraprotein levels are unreliable.
Area of Science:
- Hematology
- Clinical Chemistry
Context:
- Multiple myeloma is a cancer of plasma cells.
- Accurate monitoring of disease progression is crucial for effective treatment.
Purpose:
- To investigate the clinical utility of serum ferritin (SF) and beta 2-microglobulin (beta 2M) as biomarkers in multiple myeloma.
Summary:
- This study measured SF and beta 2M in 76 multiple myeloma patients and 70 controls.
- Both SF and beta 2M were significantly elevated in patients compared to controls.
- Correlations were found between SF, beta 2M, tumor mass, and other clinical parameters.
Impact:
- SF and beta 2M show potential as valuable tools for monitoring multiple myeloma, particularly in cases with atypical paraprotein production.
- These biomarkers may improve disease management for patients with light chain, IgE, IgD, or biclonal gammopathies.